Your First Year: A Treatment Timeline
"What does the next year of my life actually look like?" is one of the first questions almost every patient and caregiver asks after a diagnosis. There's no single answer—your path depends on your specific diagnosis, genetics, age, and how your body responds—but most journeys follow a similar rhythm of phases. This page walks through that rhythm so you know roughly what's coming and when.
This is a map, not a prediction. Timelines vary widely by disease subtype and individual response. Use this as a framework for the conversations you have with your care team, not as a substitute for their guidance.
🧭 The Journey at a Glance
📍 Diagnosis to Decision
Diagnosis (Week 0)
Diagnosis usually starts with abnormal bloodwork (a CBC) that prompts a bone marrow biopsy. Many patients are admitted to the hospital directly from this point, especially if blood counts are dangerously low or blast counts are high. The first days are a blur of tests, consults, and decisions—it's normal to feel overwhelmed.
Genetic & Molecular Testing (Week 1-2)
Samples from your bone marrow biopsy go to the lab for cytogenetics (karyotype and FISH) and a next-generation sequencing (NGS) panel that screens for dozens of mutations (FLT3, NPM1, IDH1/2, TP53, and more). This step is easy to overlook, but it quietly determines almost everything that follows—your risk category, whether a targeted drug applies to you, and whether transplant will be recommended.
Why it can feel frustrating: full NGS results often take 7-14 days, so induction frequently starts before all results are back, based on standard-of-care regimens. Results are then used to fine-tune consolidation and long-term planning. See and .
Induction (Weeks 1-6)
The most intensive phase. The goal is remission: clearing visible leukemia cells from blood and marrow. Most inpatient induction regimens (like "7+3" or FLAG-IDA) mean a hospital stay of 4-6 weeks, including a period with essentially no immune system while counts recover. Around day 14 and again around day 28-30, a follow-up bone marrow biopsy checks whether remission was achieved. Full details on regimens are on the page.
Consolidation (Months 2-4)
Once in remission, consolidation aims to eliminate any leftover, undetectable disease. This typically means 1-4 additional chemotherapy cycles, each followed by a recovery window. Depending on regimen and risk category, this phase spans roughly 2-4 months and is often where the decision about transplant or CAR-T eligibility gets finalized—donor searches and CAR-T referrals are frequently started in parallel during this phase so there's no gap in care once consolidation ends.
🔀 The Fork in the Road (Months 3-5)
This is the point where paths diverge the most. Which route you take depends on your risk category, whether a suitable donor is available, your age and overall fitness, and how your leukemia responded to induction. Many patients will only experience one of these three paths—others may end up trying more than one over time.
🏥 Allogeneic Transplant
For higher-risk disease with a matched donor available. A week of conditioning chemo/radiation, then Day 0 infusion, followed by 2-4 weeks of engraftment in or near the hospital. Full walkthrough on .
🧬 CAR-T Cell Therapy
Mainly for relapsed/refractory B-cell ALL or lymphoma. Cells are collected, sent for 3-6 weeks of manufacturing (with bridging therapy in between), then infused and followed by 1-2 weeks of close inpatient monitoring for CRS and neurological effects. Details on .
💊 Venetoclax-Based Long-Term Therapy
For patients who aren't transplant candidates (often due to age or other health conditions), an HMA + Venetoclax combination—or another continuous oral regimen—becomes an ongoing, indefinite treatment rather than a finite course. Think of it as converting leukemia into a chronic, managed condition: monthly clinic visits, periodic marrow checks, and medication that continues as long as it keeps working.
💯 The First 100 Days
If you had a transplant or CAR-T, "Day 100" is the milestone everyone counts down to—it's the point where the highest-risk complications become less likely, though vigilance continues well beyond it.
Days 0-30: The Fragile Window
Little to no immune system. Frequent clinic visits (often 2-3 times a week), transfusion support, and close monitoring for infection and, after allo transplant, early signs of acute GVHD (rash, GI symptoms, liver changes).
Days 30-100: Cautious Rebuilding
Blood counts stabilize and clinic visits space out. This is when B-cell aplasia (after CD19 CAR-T) or early graft function is assessed via chimerism testing. Immunosuppression stays in place for allo transplant patients during this window to protect the new graft.
Day 100: The Checkpoint
A formal re-evaluation: bone marrow biopsy, chimerism testing, and organ function checks. If things look good, immunosuppression tapering can begin. This is also roughly when many transplant centers say it's safer to be around again.
🌱 Months 5-12+: Into the Recovery Year
The second half of year one is about gradually stepping down medical intensity while staying watchful. It rarely feels linear—setbacks like a GVHD flare or an infection can send you back a few steps—but the general trend is toward fewer appointments and more normal days.
- Immunosuppression taper (allo transplant): typically begins around day 100 and continues over 6-12+ months if no significant GVHD develops; chronic GVHD can extend this considerably.
- Revaccination: your childhood immunity is essentially wiped out by transplant conditioning. Inactivated vaccines usually restart around 6-12 months post-transplant; live vaccines (like MMR) typically wait until immunosuppression has fully stopped, often around 24 months.
- Surveillance visits gradually space out—from weekly, to monthly, to quarterly, to annual—tracking blood counts, chimerism, and molecular/MRD markers for early relapse detection.
- Rebuilding strength: fatigue, deconditioning, and GVHD-related joint stiffness are common. See .
🔄 If the Road Forks Again: Relapse & Salvage
Routine surveillance exists specifically to catch relapse early—often at the molecular level, via MRD testing or declining donor chimerism, before it's visible on a standard blood count. If disease does come back, the options depend heavily on what's already been tried:
Donor Lymphocyte Infusion (DLI)
For patients who've had an allogeneic transplant, DLI infuses additional donor immune cells to boost the graft-versus-leukemia effect. It's often the first option tried for molecular relapse or declining chimerism, since it doesn't require another full transplant. It carries its own GVHD risk, so it's used carefully.
Second Transplant
A second allogeneic transplant (sometimes from a different donor) is possible for select patients who relapse after a first transplant, though it carries higher risk and is reserved for those fit enough to tolerate another conditioning regimen.
CAR-T Cell Therapy
If not already used, CAR-T becomes a leading option for relapsed/refractory B-cell disease, sometimes used as a bridge to a first (or second) transplant rather than as a standalone cure.
Salvage Chemotherapy & Clinical Trials
Different drug combinations, targeted agents matched to newly re-tested mutations, or enrollment in a are common next steps, especially when standard options are exhausted.
At any point where curative options become limited or no longer align with your goals, shifting focus toward is a valid and important part of this journey, not a last resort.
💊 The Long Tail: Medications That Stick Around
One of the least-discussed parts of year one is how many medications continue well after the "main" treatment ends—especially after a transplant. None of this is forever for most patients, but it's common to still be taking several daily medications at the one-year mark.
🛡️ GVHD Medications & Immunosuppressants
Tacrolimus, cyclosporine, sirolimus, or mycophenolate mofetil (MMF) prevent and control graft-versus-host disease after allogeneic transplant. Steroids (prednisone) treat flares. For steroid-refractory chronic GVHD, drugs like ruxolitinib or ibrutinib may be added. These are tapered slowly, often over 6-24 months.
🦠 Antibiotics & Antifungals
Prophylactic antibacterials (e.g., levofloxacin) and antifungals (e.g., posaconazole, voriconazole, fluconazole) guard against infection while your immune system is suppressed or still rebuilding, especially during neutropenic stretches and while on high-dose steroids.
🧫 Antivirals
Acyclovir or valacyclovir prevent HSV/VZV (shingles) reactivation, often continued for a year or more. Letermovir is commonly used for CMV prophylaxis in the first 100 days after allogeneic transplant, when CMV reactivation risk is highest.
🩺 PJP Prophylaxis & Immune Support
Trimethoprim-sulfamethoxazole (Bactrim), dapsone, atovaquone, or inhaled pentamidine prevent Pneumocystis pneumonia (PJP) during immunosuppression. Patients with significant B-cell aplasia (common after CD19 CAR-T) may need periodic IVIG (intravenous immunoglobulin) infusions to maintain antibody levels.
💉 Revaccination
Transplant essentially resets your immune "memory," so childhood vaccines are re-given on a schedule—inactivated vaccines starting around 6-12 months post-transplant, live vaccines (MMR, varicella) only after immunosuppression fully stops, typically around 24 months.
🧪 Long-Term Maintenance Therapy
For those on a Venetoclax-based or TKI-based track, or ALL patients on oral maintenance (e.g., 6-mercaptopurine and methotrexate for 2-3 years), the "main treatment" doesn't really end—it becomes a long-term daily routine with periodic lab monitoring. See for how each drug class works.